Sotagliflozin, a new drug for heart failure, has been approved by the FDA.

Published Date: 27 May 2023

A novel SGLT 1 and 2 inhibitor called sotagliflozin has been approved for use in the US market with the goal of reducing the risk of cardiovascular (CV) events, particularly hospitalizations for heart failure and acute exacerbations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot